Bronnen:
- Facon T, Kumar SK, Plesner T, et al. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA). ASH Annual Meeting and Exposition 2018, abstract LBA-2.,Palumbo A, Chanan-Khan A, Weisel K, et al.; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754-66.,Dimopoulos MA, Oriol A, Nahi H, et al.; POLLUX Investigators. daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319-31. ,Mateos MV, Dimopoulos MA, Cavo M, et al.; ALCYONE Trial Investigators. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518-28.